TRPV1, PPAR and SGLT-2 as a Potential Therapeutic Target for Diabetes Mellitus: Current Status and Challenges

Abstract

A chronic pathological condition; diabetes mellitus occurs in almost 90% of all diabetic cases globally. It is estimated that the number of diabetes patients will rise from 382 million in 2013 to 592 million by 2035 as per the data published by the Current International Diabetes Federation. Daily life style and day to day unhealthy food habits, diabetes is prevalent among the young people too along with the aged people due to their ageing. Diabetes mellitus is a disorder where there is insufficiency of insulin having the symptoms excessive thirst, frequent urination, fatigue, weight loss, results in blood sugar level to be drastically high. One may observe a drastic increase in blood glucose level which lead to various types of health complications like retinopathy, nerve damage etc. Various treatment strategies are available among these the modern treatment strategy includes sulfonylureas, GLP-1 agonist, DPP4- inhibitors, metformin, PPAR-γ agonists, bariatric surgery etc. In this review, we will highlight various potential therapeutic targets including TRPV1, PPAR, and SGLT-2 to mitigate diabetes mellitus.